FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone ...

The global Injectable Drug Delivery Market, valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4%, reaching US$690.23 billion in 2025 and an impressive US$1,034.78 billion ...

Special discount programmes are available for each of the biologic DMARDs, but the high cost of these drugs limits access ... Golimumab (Simponi; Centocor), the first once-monthly, self-injectable ...

Shuttle-based therapies are under active development for an array of brain conditions. “It’s now abundantly clear that we can ...

Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will ...

South Korean drug maker Samsung BioLogics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The facility’s products will include biologic drugs and a new, easier-to-use version of Keytruda, the company’s blockbuster cancer drug. The plant marks Merck’s first in-house manufacturing ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said. Merck said last week its biggest ...

Kinlytic is already approved for clinical use in the U.S. and the parties’ work is to validate new manufacturing for the drug and to re-enter the market by way of a supplemental biologics ...

For small molecule drugs (chemical compounds that are usually pills, e.g. empagliflozin [Jardiance]), prices are negotiated at year 7 and take effect 9 years after FDA approval. For biologics ...